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REPLY
We thank Dr. Schneider and colleagues for their interest in our
study evaluating the effect of percutaneous left atrial appendage
transcatheter occlusion (PLAATO) on left atrial (LA) structure
and function (1). They list “several points of criticism” deserving of
comment.
Our study population is part of the cohort of patients in the
PLAATO feasibility trial. The report was based on all but one of
the U.S. patients who had completed six-month follow-up. Mea-
surements were available on a majority of patients (70% at six
months) (1). Data analysis showed no statistically significant
change in pulmonary venous flow or diastolic transmitral flow
following PLAATO. As described in our methods, LA size was
carefully measured at each time point. Though not included in the
final report, no significant change occurred compared to baseline.
Interesting endocrine functions of the left atrial appendage
(LAA) have been detailed by Stöllberger et al. (2). Human data on
atrial appendectomy are limited. To our knowledge no data
suggest detrimental clinical effects of LAA occlusion attributable to
a decrease in atrial natriuretic peptide. Yoshihara and colleagues
have indicated that exclusion of the LAA without exclusion of the
right atrial appendage has even less effect (3,4). Data concerning
endocrine LAA function were not part of the PLAATO trial and
remains an interesting area for research.
The circumflex coronary artery is variable in its relation to the
LAA. The artery runs in the atrioventricular groove and is
separated from the base of the LAA by atrial tissue. Oversizing of
an occlusion device could theoretically result in arterial compres-
sion. We used careful angiographic and echocardiographic sizing.
This and postimplant residual flow around PLAATO make
compromise of circumflex flow unlikely. Clinical data so far
support this.
Finally, Dr. Schneider and colleagues re-emphasize the point
that we made in our Discussion section. The impact of minimal
residual flow around the device on the occurrence of stroke has to
be assessed when the clinical follow-up is reported.
The aim of our study was to show no detrimental effect of
PLAATO on pulmonary vein flow and diastolic transmitral flow
in our patient population. Clinical follow-up data will be reported
for the entire PLAATO cohort. We agree that long-term data will
help answer many questions about the efficacy of PLAATO, but
we believe that percutaneous LAA occlusion will offer an impor-
tant option for selected patients with atrial fibrillation.
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Is Aspirin Resistance or
Female Gender Associated
With a High Incidence of
Myonecrosis After Nonurgent
Percutaneous Coronary Intervention?
We have with great interest read the report by Chen et al. (1)
published in the March 17 issue of the Journal. The prevalence of
aspirin resistance among patients with different manifestations of
atherosclerosis has been well established. However, studies ad-
dressing the clinical relevance of aspirin resistance are still lacking.
Therefore, studies as the one performed by Chen et al. (1) should
be appreciated.
To understand the clinical importance of the results presented,
however, we will take this opportunity to ask the investigators
whether the gender of the patients was included in the multivariate
analysis identifying independent predictors of creatine kinase-
myocardial band (CK-MB) elevation after percutaneous coronary
intervention (PCI)?
Female gender has been proposed to be a risk factor for
mortality and morbidity in relation to the performance of PCI
(2,3). This observation has been partly explained by older age,
more severe heart failure, an increased prevalence of co-morbidity,
and the presence of smaller coronary arteries in women compared
with men.
Chen et al. (1) showed that aspirin resistance is significantly
more prevalent in female (44.8%) than in male patients (19.7%).
This difference between genders in the occurrence of aspirin
resistance may in part account for the observed increased risk for
experiencing complications in relation to the PCI procedure (1).
Unfortunately, from the data presented it is not possible to decide
whether gender was included in the multivariate analysis. To put
the results of the study by Chen et al. (1) into an appropriate
clinical perspective, we would like the investigators to inform
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us—and other readers—whether gender independently influenced
clinical outcome.
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We would like to thank Dr. Poulsen and colleagues for their
interest in our study (1). The prevalence of female gender with or
without creatine kinase-myocardial band (CK-MB) elevation after
percutaneous coronary intervention (PCI) was not different be-
tween the two groups (31.1% vs. 21.7%; p  0.22). Gender was
entered in the multivariate analysis, and it turned out not to be an
independent predictor of CK-MB elevation.
Women undergoing balloon angioplasty had a higher incidence
of early adverse cardiac events in both early (2) and contemporary
series (3). In the current era of predominant stent implantation for
PCI, mixed results have been demonstrated (4–6). However, our
data concur with recent studies specifically addressing post-PCI
myonecrosis, in which female gender is not demonstrated to be an
independent correlate of post-PCI myonecrosis (7–9).
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